Database release
The following changes were made to the Molecular Oncology Almanac in this release -
Added entries:
- (FDA) ERBB2 amplifications and sensitivity to pembrolizumab in combination with fluoropyrimidine, trastuzumab, and platinum-based chemotherapy in gastric or gastroesophageal junction adenocarcinoma.
- (Inferential) CD274 amplifications and sensitivity to pembrolizumab in gastric or gastroesophageal junction adenocarcinoma.
Edited entries:
- (Clinical evidence) NF1 germline variants associated with radiation therapy was not labeled with a clinical assertion. “1” has been set for adverse_event_risk.
- (Inferential) ERBB2 amplification and sensitivity to trastuzumab was changed to an inferential assertion from FDA. The description was also updated for these entries.